YIH
CATX icon

Y-Intercept (HK)’s Perspective Therapeutics CATX Stock Holding History

Y-Intercept (HK)’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,263
Closed -$32.7K – 1231
2024
Q4 		$32.7K Buy
+10,263
New +$83.8K ﹤0.01% 1124
2024
Q3 		– Sell
-63,581
Closed -$634K – 1346
2024
Q2 		$634K Buy
+63,581
New +$919K 0.03% 717

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Y-Intercept (HK)'s CATX Position: Q1 2025 in Review

Y-Intercept (HK) sold out of Perspective Therapeutics (CATX) in Q1 2025, closing a stake of 10,263 shares — an estimated $32.7K sold.

Y-Intercept (HK) first reported a position in CATX in Q2 2024 and held it in 2 quarters. The position peaked at $634K in Q2 2024. 112 funds tracked by Wall St. Rank hold CATX as of Q1 2025.

  • Y-Intercept (HK) reported no remaining Perspective Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 10,263 Perspective Therapeutics shares in Q1 2025, an estimated $32.7K.
  • Y-Intercept (HK) first reported a position in Perspective Therapeutics in Q2 2024 and held it in 2 quarters.
  • Y-Intercept (HK)'s Perspective Therapeutics position peaked at $634K in Q2 2024.
  • 112 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2025.

Based on Y-Intercept (HK)'s 13F filing for Q1 2025, filed 6 May 2025.